What's new

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised

May 15, 2025 - 10:34
 0
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised
Read More

Tags:

Previous Article

Questions and answers clinic on Product Management Service (PMS) Product User In...

Next Article

Fourteenth meeting of the industry stakeholder platform on the operation of the ...

Related Posts

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – May 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 May 2025, 10:00 (CEST) to 21 May 2025, 11:30 (CEST)

Meeting of the Executive Steering Group on Shortages an...

May 15, 2025  0

Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Date of authorisation: 28/08/2000, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR...

May 6, 2025  0

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 December 2025, 11:00 (CET) to 18 December 2025, 12:00 (CET)

Questions and answers clinic on Product Management Serv...

May 15, 2025  0